☆ 4.6 Article

Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma-The RAPPORT Trial

EUROPEAN UROLOGY (2022)

Related references

Note: Only part of the references are listed.

Review Oncology

Safety and Survival Rates Associated With Ablative Stereotactic Radiotherapy for Patients With Oligometastatic Cancer A Systematic Review and Meta-analysis

Eric J. Lehrer et al.

Summary: The meta-analysis shows that stereotactic ablative radiotherapy is relatively safe and clinically beneficial in patients with oligometastatic cancer, with low rates of toxic effects and acceptable survival rates. Further research is needed to validate these findings.

JAMA ONCOLOGY (2021)

Add to Collection

Article Oncology

Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma

David F. McDermott et al.

Summary: Single-agent pembrolizumab demonstrated promising antitumor activity as a first-line treatment in untreated patients with advanced ccRCC, with durable responses observed across different categories. The safety and tolerability profile of pembrolizumab monotherapy was consistent with what has been observed in other tumor types.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

T. K. Choueiri et al.

Summary: The study demonstrates that nivolumab plus cabozantinib has significant advantages over sunitinib in the treatment of previously untreated advanced renal-cell carcinoma, including progression-free survival, overall survival, and likelihood of response.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

Robert Motzer et al.

Summary: The study demonstrated that the combination of lenvatinib with pembrolizumab led to significantly longer progression-free survival and overall survival than sunitinib, while the combination of lenvatinib with everolimus showed longer progression-free survival but not overall survival compared to sunitinib. Adverse events were more frequent in patients receiving lenvatinib-based treatments.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Letter Oncology

Temporal Trends and Predictors in the Use of Stereotactic Body Radiotherapy for Treatment of Metastatic Renal Cell Carcinoma in the US

Marco Paciotti et al.

ONCOLOGIST (2021)

Add to Collection

Article Urology & Nephrology

Stereotactic Radiotherapy for Oligoprogression in Metastatic Renal Cell Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Phase 2 Prospective Multicenter Study

Patrick Cheung et al.

Summary: SRT for oligoprogressive metastatic renal cell carcinoma (mRCC) lesions in patients on tyrosine kinase inhibitor (TKI) therapy showed high local control (LC) and delayed the need to change systemic therapy.

EUROPEAN UROLOGY (2021)

Add to Collection

Article Medicine, Research & Experimental

A phase I/II study of stereotactic radiotherapy and pembrolizumab for oligometastatic renal tumours (RAPPORT): Clinical trial protocol

David Pryor et al.

Summary: The RAPPORT study aims to evaluate the safety, efficacy, and biological effects of the combination of SABR and pembrolizumab in oligometastatic ccRCC, providing important data on this combination therapy and insights into its underlying mechanisms.

CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS (2021)

Add to Collection

Article Oncology

Impact of metastasectomy on progression free and overall survival in metastatic renal cell carcinoma: Analysis of the REMARCC registry.

Margaret Frances Meagher et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Oncology

Combination of dual immune checkpoint inhibition (ICI) with stereotactic radiation (SBRT) in metastatic renal cell carcinoma (mRCC) (RADVAX RCC).

Hans J. Hammers et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Urology & Nephrology

European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update

Borje Ljungberg et al.

EUROPEAN UROLOGY (2019)

Add to Collection

Article Medicine, General & Internal

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Brian I. Rini et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Meeting Abstract Oncology

Randomized, double-blind phase III study of pazopanib versus placebo in patients with metastatic renal cell carcinoma who have no evidence of disease following metastasectomy: A trial of the ECOG-ACRIN cancer research group (E2810).

Leonard Joseph Appleman et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Article Oncology

A Retrospective Analysis of the Impact of Metastasectomy on Prognostic Survival According to Metastatic Organs in Patients With Metastatic Renal Cell Carcinoma

Sung Han Kim et al.

FRONTIERS IN ONCOLOGY (2019)

Add to Collection

Review Urology & Nephrology

The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis

Rohann J. M. Correa et al.

EUROPEAN UROLOGY FOCUS (2019)

Add to Collection

Review Medicine, General & Internal

Radiotherapy and immunotherapy: a synergistic effect in cancer care

Guy-Anne Turgeon et al.

MEDICAL JOURNAL OF AUSTRALIA (2019)

Add to Collection

Article Oncology

Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studies

Nicholas G. Zaorsky et al.

EUROPEAN UROLOGY ONCOLOGY (2019)

Add to Collection

Review Oncology

Surgical Metastasectomy in Renal Cell Carcinoma: A Systematic Review

Idir Ouzaid et al.

EUROPEAN UROLOGY ONCOLOGY (2019)

Add to Collection

Article Medicine, General & Internal

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

R. J. Motzer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Review Oncology

Using immunotherapy to boost the abscopal effect

Wilfred Ngwa et al.

NATURE REVIEWS CANCER (2018)

Add to Collection

Article Oncology

Kidney Cancer, Version 2.2017 Clinical Practice Guidelines in Oncology

Robert J. Motzer et al.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2017)

Add to Collection

Review Urology & Nephrology

Radiotherapy for renal cell carcinoma: renaissance of an overlooked approach

Shankar Siva et al.

NATURE REVIEWS UROLOGY (2017)

Add to Collection

Article Oncology

RECIST 1.1-Update and clarification: From the RECIST committee

Lawrence H. Schwartz et al.

EUROPEAN JOURNAL OF CANCER (2016)

Add to Collection

Article Oncology

Current clinical trials testing the combination of immunotherapy with radiotherapy

Josephine Kang et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)

Add to Collection

Review Oncology

Abscopal effects of radiation therapy: A clinical review for the radiobiologist

Shankar Siva et al.

CANCER LETTERS (2015)

Add to Collection

Article Oncology

External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study

Daniel Y. C. Heng et al.

LANCET ONCOLOGY (2013)

Add to Collection

Article Oncology

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. A. Eisenhauer et al.

EUROPEAN JOURNAL OF CANCER (2009)

Add to Collection

© Peeref 2019-2024. All rights reserved.